RS62415B1 - Farmaceutski oblici i metode koji se odnose na piridinoilpiperidin 5-ht1f agoniste - Google Patents

Farmaceutski oblici i metode koji se odnose na piridinoilpiperidin 5-ht1f agoniste

Info

Publication number: RS62415B1
Authority: RS; Serbia
Prior art keywords: pyridinoylpiperidine; compositions; methods related; ht1f agonists; ht1f
Prior art date: 2016-12-06

Application number

RS20211233A

Other languages

English (en)

Inventor

Brigida Allieri

Paul Fagan

Emma Sharp

Raymond D Skwierczynski

Original Assignee

Colucid Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-12-06

Filing date

2017-12-05

Publication date

2021-10-29

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60972336&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS62415(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2017-12-05 Application filed by Colucid Pharmaceuticals Inc filed Critical Colucid Pharmaceuticals Inc

2021-10-29 Publication of RS62415B1 publication Critical patent/RS62415B1/sr

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Biomedical Technology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Pain & Pain Management (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Hydrogenated Pyridines (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

RS20211233A 2016-12-06 2017-12-05 Farmaceutski oblici i metode koji se odnose na piridinoilpiperidin 5-ht1f agoniste RS62415B1 (sr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201662430662P	2016-12-06	2016-12-06
EP17829372.6A EP3551617B1 (en)	2016-12-06	2017-12-05	Compositions and methods related to pyridinoylpiperidine 5-ht1f agonists
PCT/US2017/064652 WO2018106657A1 (en)	2016-12-06	2017-12-05	Compositions and methods related to pyridinoylpiperidine 5-ht1f agonists

Publications (1)

Publication Number	Publication Date
RS62415B1 true RS62415B1 (sr)	2021-10-29

Family

ID=60972336

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
RS20211233A RS62415B1 (sr)	2016-12-06	2017-12-05	Farmaceutski oblici i metode koji se odnose na piridinoilpiperidin 5-ht1f agoniste

Country Status (38)

Country	Link
US (1)	US11053214B2 (sr)
EP (1)	EP3551617B1 (sr)
JP (4)	JP2020500936A (sr)
KR (3)	KR20210102497A (sr)
CN (3)	CN115385893A (sr)
AU (1)	AU2017373784B2 (sr)
BR (1)	BR112019010934A2 (sr)
CA (1)	CA3043772C (sr)
CL (1)	CL2019001426A1 (sr)
CO (1)	CO2019005290A2 (sr)
CR (1)	CR20190251A (sr)
CY (1)	CY1124540T1 (sr)
DK (1)	DK3551617T3 (sr)
DO (1)	DOP2019000139A (sr)
EA (1)	EA201991112A1 (sr)
EC (1)	ECSP19040190A (sr)
ES (1)	ES2889476T3 (sr)
HR (1)	HRP20211557T1 (sr)
HU (1)	HUE056820T2 (sr)
IL (1)	IL266598B2 (sr)
JO (1)	JOP20190129B1 (sr)
LT (1)	LT3551617T (sr)
MA (1)	MA52920B1 (sr)
MD (1)	MD3551617T2 (sr)
MX (2)	MX2019006520A (sr)
MY (1)	MY196855A (sr)
NZ (1)	NZ752906A (sr)
PE (2)	PE20241297A1 (sr)
PH (1)	PH12019501252B1 (sr)
PL (1)	PL3551617T3 (sr)
PT (1)	PT3551617T (sr)
RS (1)	RS62415B1 (sr)
SI (1)	SI3551617T1 (sr)
TN (1)	TN2019000174A1 (sr)
TW (1)	TWI671290B (sr)
UA (1)	UA124433C2 (sr)
WO (1)	WO2018106657A1 (sr)
ZA (1)	ZA201903449B (sr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TWI826514B (zh)	2018-09-04	2023-12-21	美商美國禮來大藥廠	用於預防偏頭痛之拉米迪坦(lasmiditan)長期夜間投藥
TWI776175B (zh)	2019-07-09	2022-09-01	美商美國禮來大藥廠	大規模製備2,4,6-三氟-n-[6-(1-甲基-哌啶-4-羰基)-吡啶-2-基]-苯甲醯胺半琥珀酸鹽的方法及中間體，以及2,4,6-三氟-n-[6-(1-甲基-哌啶-4-羰基)-吡啶-2-基]-苯甲醯胺醋酸鹽之製備
CN111004214B (zh) *	2019-11-22	2021-06-08	广东东阳光药业有限公司	吡啶酰基哌啶衍生物及其用途
BR112023022680A2 (pt)	2021-05-07	2024-01-23	Lilly Co Eli	Composições com sabor mascarado de hemissuccinato de 2,4,6-trifluoro-n-[6-(1-metil-piperidin-4-carbonil)-piridin-2-il]-benzamida, comprimido desintegrante oralmente compreendendo o mesmo, seus usos, e processo para fabricação de comprimido
CN116270505A (zh) *	2021-12-20	2023-06-23	南京科默生物医药有限公司	含半琥珀酸拉司米地坦的口服固体制剂及其3d打印制备技术

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5023252A (en)	1985-12-04	1991-06-11	Conrex Pharmaceutical Corporation	Transdermal and trans-membrane delivery of drugs
US5011472A (en)	1988-09-06	1991-04-30	Brown University Research Foundation	Implantable delivery system for biological factors
TWI263497B (en)	2002-03-29	2006-10-11	Lilly Co Eli	Pyridinoylpiperidines as 5-HT1F agonists
US20060178349A1 (en)	2005-01-24	2006-08-10	Pozen Inc.	Compositions and therapeutic methods utilizing a combination of a 5-HT1F inhibitor and an NSAID
US20100256187A1 (en)	2009-04-02	2010-10-07	Colucid Pharmaceuticals, Inc.	Composition of 2,4,6- trifluoro-n-[6-(1-methyl-piperidin-4-carbonyl)-pyridin-2-yl]-benzamide
US8697876B2 (en)	2010-04-02	2014-04-15	Colucid Pharmaceuticals, Inc.	Compositions and methods of synthesis of pyridinolypiperidine 5-HT1F agonists
WO2012163365A1 (en)	2011-06-01	2012-12-06	Concit Pharma Aps	Combinations of serotonin receptor agonists for treatment of movement disorders
WO2018010345A1 (zh)	2016-07-15	2018-01-18	杭州领业医药科技有限公司	一种受体激动剂的晶型及其制备方法和药物组合物
TWI754772B (zh)	2017-09-06	2022-02-11	美商美國禮來大藥廠	用於治療偏頭痛之拉米迪坦(lasmiditan)與cgrp拮抗劑之組合療法

2017
- 2017-12-05 US US16/467,208 patent/US11053214B2/en active Active
- 2017-12-05 PT PT17829372T patent/PT3551617T/pt unknown
- 2017-12-05 JO JOP/2019/0129A patent/JOP20190129B1/ar active
- 2017-12-05 CR CR20190251A patent/CR20190251A/es unknown
- 2017-12-05 IL IL266598A patent/IL266598B2/en unknown
- 2017-12-05 KR KR1020217025499A patent/KR20210102497A/ko not_active Ceased
- 2017-12-05 MY MYPI2019003189A patent/MY196855A/en unknown
- 2017-12-05 MX MX2019006520A patent/MX2019006520A/es unknown
- 2017-12-05 PE PE2023002466A patent/PE20241297A1/es unknown
- 2017-12-05 SI SI201730881T patent/SI3551617T1/sl unknown
- 2017-12-05 NZ NZ752906A patent/NZ752906A/en unknown
- 2017-12-05 PL PL17829372T patent/PL3551617T3/pl unknown
- 2017-12-05 AU AU2017373784A patent/AU2017373784B2/en active Active
- 2017-12-05 WO PCT/US2017/064652 patent/WO2018106657A1/en active Application Filing
- 2017-12-05 BR BR112019010934A patent/BR112019010934A2/pt not_active Application Discontinuation
- 2017-12-05 UA UAA201905483A patent/UA124433C2/uk unknown
- 2017-12-05 MA MA52920A patent/MA52920B1/fr unknown
- 2017-12-05 JP JP2019551251A patent/JP2020500936A/ja active Pending
- 2017-12-05 MD MDE20191169T patent/MD3551617T2/ro unknown
- 2017-12-05 CA CA3043772A patent/CA3043772C/en active Active
- 2017-12-05 CN CN202210944298.6A patent/CN115385893A/zh active Pending
- 2017-12-05 RS RS20211233A patent/RS62415B1/sr unknown
- 2017-12-05 PE PE2019001167A patent/PE20191134A1/es unknown
- 2017-12-05 PH PH1/2019/501252A patent/PH12019501252B1/en unknown
- 2017-12-05 ES ES17829372T patent/ES2889476T3/es active Active
- 2017-12-05 LT LTEPPCT/US2017/064652T patent/LT3551617T/lt unknown
- 2017-12-05 DK DK17829372.6T patent/DK3551617T3/da active
- 2017-12-05 EA EA201991112A patent/EA201991112A1/ru unknown
- 2017-12-05 KR KR1020227046438A patent/KR20230008257A/ko not_active Ceased
- 2017-12-05 CN CN202210944373.9A patent/CN115385894A/zh active Pending
- 2017-12-05 TW TW106142535A patent/TWI671290B/zh active
- 2017-12-05 MX MX2021014139A patent/MX2021014139A/es unknown
- 2017-12-05 EP EP17829372.6A patent/EP3551617B1/en active Active
- 2017-12-05 CN CN201780075750.7A patent/CN110291079A/zh active Pending
- 2017-12-05 TN TNP/2019/000174A patent/TN2019000174A1/en unknown
- 2017-12-05 HU HUE17829372A patent/HUE056820T2/hu unknown
- 2017-12-05 KR KR1020197016255A patent/KR20190075130A/ko active Application Filing
- 2017-12-05 HR HRP20211557TT patent/HRP20211557T1/hr unknown
2019
- 2019-05-23 CO CONC2019/0005290A patent/CO2019005290A2/es unknown
- 2019-05-27 CL CL2019001426A patent/CL2019001426A1/es unknown
- 2019-05-30 ZA ZA2019/03449A patent/ZA201903449B/en unknown
- 2019-05-30 DO DO2019000139A patent/DOP2019000139A/es unknown
- 2019-06-06 EC ECSENADI201940190A patent/ECSP19040190A/es unknown
2021
- 2021-09-22 JP JP2021153729A patent/JP2022000451A/ja active Pending
- 2021-10-05 CY CY20211100864T patent/CY1124540T1/el unknown
2023
- 2023-06-26 JP JP2023104019A patent/JP7561240B2/ja active Active
2024
- 2024-09-20 JP JP2024163884A patent/JP2024178323A/ja active Pending

Also Published As

Publication number	Publication date
NZ752906A (en)	2021-07-30
PL3551617T3 (pl)	2021-12-20
MA52920B1 (fr)	2021-11-30
JP2020500936A (ja)	2020-01-16
PH12019501252B1 (en)	2024-05-24
MX2021014139A (es)	2022-05-24
EP3551617A1 (en)	2019-10-16
CA3043772A1 (en)	2018-06-14
MD3551617T2 (ro)	2021-12-31
IL266598B1 (en)	2024-01-01
PE20241297A1 (es)	2024-06-24
MA52920A (fr)	2021-04-28
JP7561240B2 (ja)	2024-10-03
KR20210102497A (ko)	2021-08-19
CA3043772C (en)	2022-06-07
PT3551617T (pt)	2021-10-04
PE20191134A1 (es)	2019-09-02
LT3551617T (lt)	2021-10-11
SI3551617T1 (sl)	2021-11-30
MY196855A (en)	2023-05-05
BR112019010934A2 (pt)	2019-10-01
PH12019501252A1 (en)	2019-12-02
US20200087279A1 (en)	2020-03-19
IL266598A (en)	2019-07-31
CL2019001426A1 (es)	2019-10-11
ECSP19040190A (es)	2019-08-30
JP2024178323A (ja)	2024-12-24
MX2019006520A (es)	2019-08-21
US11053214B2 (en)	2021-07-06
TN2019000174A1 (en)	2020-10-05
CN115385893A (zh)	2022-11-25
HUE056820T2 (hu)	2022-03-28
AU2017373784A1 (en)	2019-05-16
JP2023123678A (ja)	2023-09-05
CN110291079A (zh)	2019-09-27
EA201991112A1 (ru)	2019-10-31
EP3551617B1 (en)	2021-08-11
CY1124540T1 (el)	2022-07-22
DOP2019000139A (es)	2019-08-15
KR20230008257A (ko)	2023-01-13
ZA201903449B (en)	2021-02-24
JOP20190129B1 (ar)	2023-03-28
CN115385894A (zh)	2022-11-25
CR20190251A (es)	2019-08-26
JP2022000451A (ja)	2022-01-04
TW201833097A (zh)	2018-09-16
UA124433C2 (uk)	2021-09-15
HRP20211557T1 (hr)	2022-01-07
AU2017373784B2 (en)	2020-04-23
KR20190075130A (ko)	2019-06-28
DK3551617T3 (da)	2021-09-13
IL266598B2 (en)	2024-05-01
JOP20190129A1 (ar)	2019-05-29
WO2018106657A1 (en)	2018-06-14
CO2019005290A2 (es)	2019-05-31
ES2889476T3 (es)	2022-01-12
TWI671290B (zh)	2019-09-11

Publication	Publication Date	Title
HRP20192145T1 (hr)	2020-05-15	Pripravci nosača-antitijela i metode pripreme i uporabe istih
IL259576A (en)	2018-07-31	Preparations and methods for immuno-oncology
ZA201801762B (en)	2019-01-30	Papermaking additive compositions and methods and uses thereof
GB2546350B (en)	2019-12-04	Compositions and methods
GB2535253B (en)	2019-04-17	Compositions and methods
GB2535423B (en)	2021-06-23	Cementing compositions and methods
GB201718876D0 (en)	2017-12-27	Antithrombin-heparin compositions and methods
GB201417828D0 (en)	2014-11-19	New methods and compositions
HK1246193A1 (zh)	2018-09-07	用於改善認知的方法和組合物
ZA201903449B (en)	2021-02-24	Compositions and methods related to pyridinoylpiperidine 5-ht1f agonists
IL257458B1 (en)	2023-09-01	dpep-1 binding compositions and methods of use
HK1254028A1 (zh)	2019-07-12	抗瘧疾組合物和方法
PL3209828T3 (pl)	2021-03-08	Kompozycje włókniste zawierające n-halamine i ich zastosowanie
GB201705626D0 (en)	2017-05-24	Compositions and methods
HK1250015A1 (zh)	2018-11-23	鎮咳藥組合物和方法
ZA201807665B (en)	2020-02-26	Methods and compositions
GB201715820D0 (en)	2017-11-15	Compositions and methods
GB201512996D0 (en)	2015-09-09	Compositions and methods
GB201514413D0 (en)	2015-09-30	Compositions and methods
GB201402915D0 (en)	2014-04-02	Compositions and methods
ZA201807782B (en)	2020-05-27	Methods and compositions
IL256261B (en)	2022-06-01	Hide1 compositions and methods
GB201522554D0 (en)	2016-02-03	Methods and compositions
GB201518167D0 (en)	2015-11-25	Methods and compositions
GB201514415D0 (en)	2015-09-30	Compositions and methods